Insider Selling: Kalvista Pharmaceuticals Inc (KALV) Insider Sells 4,000 Shares of Stock

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) insider Edward P. Feener sold 4,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $24.92, for a total value of $99,680.00. Following the completion of the transaction, the insider now directly owns 100,950 shares in the company, valued at approximately $2,515,674. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ KALV opened at $25.50 on Friday. Kalvista Pharmaceuticals Inc has a 1 year low of $7.73 and a 1 year high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. The company had revenue of $3.89 million for the quarter, compared to analysts’ expectations of $3.97 million. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. Research analysts anticipate that Kalvista Pharmaceuticals Inc will post -1.43 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of KALV. Flinton Capital Management LLC acquired a new stake in Kalvista Pharmaceuticals during the 4th quarter valued at $26,000. Ramsey Quantitative Systems acquired a new stake in Kalvista Pharmaceuticals during the 4th quarter valued at $35,000. Bank of Montreal Can acquired a new stake in Kalvista Pharmaceuticals during the 4th quarter valued at $90,000. Virtu Financial LLC acquired a new stake in Kalvista Pharmaceuticals during the 3rd quarter valued at $216,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Kalvista Pharmaceuticals during the 3rd quarter valued at $274,000. 77.37% of the stock is currently owned by institutional investors.

Several research analysts have issued reports on KALV shares. Needham & Company LLC started coverage on Kalvista Pharmaceuticals in a report on Wednesday, March 20th. They issued a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research raised Kalvista Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 price target on the stock in a report on Saturday, March 2nd. BidaskClub cut Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. Finally, ValuEngine raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Kalvista Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $28.60.

TRADEMARK VIOLATION NOTICE: This story was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/insider-selling-kalvista-pharmaceuticals-inc-kalv-insider-sells-4000-shares-of-stock.html.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More: What is a Call Option?

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.